A	a	O	O	O	O
phase	phase	O	O	O	O
I	i	O	O	O	O
study	study	O	O	O	O
of	of	O	O	O	O
4'-0-tetrahydropyranyladriamycin	4'-0-tetrahydropyranyladriamycin	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Clinical	clinical	O	O	O	O
pharmacology	pharmacology	O	O	O	O
and	and	O	O	O	O
pharmacokinetics	pharmacokinetics	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
Phase	phase	O	O	O	O
I	i	O	O	O	O
study	study	O	O	O	O
of	of	O	O	O	O
intravenous	intravenous	O	O	O	O
(	(	O	O	O	O
IV	iv	O	O	O	O
)	)	O	O	O	O
bolus	bolus	O	O	O	O
4'-0-tetrahydropyranyladriamycin	4'-0-tetrahydropyranyladriamycin	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
Pirarubicin	pirarubicin	O	O	OTHERS	I
)	)	O	O	O	O
was	was	O	O	O	O
done	done	O	O	O	O
in	in	O	O	O	O
55	55	O	O	O	O
patients	patients	O	O	O	O
in	in	O	O	O	O
good	good	O	O	O	O
performance	performance	O	O	O	O
status	status	O	O	O	O
with	with	O	O	O	O
refractory	refractory	O	O	O	O
tumors	tumors	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Twenty-six	twenty-six	O	O	O	O
had	had	O	O	O	O
minimal	minimal	O	O	O	O
prior	prior	O	O	O	O
therapy	therapy	O	O	O	O
(	(	O	O	O	O
good	good	O	O	O	O
risk	risk	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
23	23	O	O	O	O
had	had	O	O	O	O
extensive	extensive	O	O	O	O
prior	prior	O	O	O	O
therapy	therapy	O	O	O	O
(	(	O	O	O	O
poor	poor	O	O	O	O
risk	risk	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
six	six	O	O	O	O
had	had	O	O	O	O
renal	renal	O	O	O	O
and/or	and/or	O	O	O	O
hepatic	hepatic	O	O	OTHERS	I
dysfunction	dysfunction	O	O	OTHERS	I
.	.	O	O	O	O

A	a	O	O	O	O
total	total	O	O	O	O
of	of	O	O	O	O
167	167	O	O	O	O
courses	courses	O	O	O	O
at	at	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
15	15	O	O	O	O
to	to	O	O	O	O
70	70	O	O	O	O
mg/m2	mg/m2	O	O	O	O
were	were	O	O	O	O
evaluable	evaluable	O	O	O	O
.	.	O	O	O	O

Maximum	maximum	O	O	O	O
tolerated	tolerated	O	O	O	O
dose	dose	O	O	O	O
in	in	O	O	O	O
good-risk	good-risk	O	O	O	O
patients	patients	O	O	O	O
was	was	O	O	O	O
70	70	O	O	O	O
mg/m2	mg/m2	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
in	in	O	O	O	O
poor-risk	poor-risk	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
60	60	O	O	O	O
mg/m2	mg/m2	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
dose-limiting	dose-limiting	O	O	O	O
toxic	toxic	O	O	O	O
effect	effect	O	O	O	O
was	was	O	O	O	O
transient	transient	O	O	O	O
noncumulative	noncumulative	O	O	O	O
granulocytopenia	granulocytopenia	O	O	OTHERS	I
.	.	O	O	O	O

Granulocyte	granulocyte	O	O	O	O
nadir	nadir	O	O	O	O
was	was	O	O	O	O
on	on	O	O	O	O
day	day	O	O	O	O
14	14	O	O	O	O
(	(	O	O	O	O
range	range	O	O	O	O
,	,	O	O	O	O
4	4	O	O	O	O
-	-	O	O	O	O
22	22	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Less	less	O	O	O	O
frequent	frequent	O	O	O	O
toxic	toxic	O	O	O	O
effects	effects	O	O	O	O
included	included	O	O	O	O
thrombocytopenia	thrombocytopenia	O	DISEASE	OTHERS	I
,	,	O	O	O	O
anemia	anemia	O	DISEASE	OTHERS	I
,	,	O	O	O	O
nausea	nausea	O	DISEASE	OTHERS	I
,	,	O	O	O	O
mild	mild	O	O	O	O
alopecia	alopecia	O	O	OTHERS	I
,	,	O	O	O	O
phlebitis	phlebitis	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
mucositis	mucositis	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Myelosuppression	myelosuppression	O	DISEASE	OTHERS	I
was	was	O	O	O	O
more	more	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
hepatic	hepatic	O	O	OTHERS	I
dysfunction	dysfunction	O	O	OTHERS	I
.	.	O	O	O	O

Pharmacokinetic	pharmacokinetic	O	O	O	O
analyses	analyses	O	O	O	O
in	in	O	O	O	O
21	21	O	O	O	O
patients	patients	O	O	O	O
revealed	revealed	O	O	O	O
Pirarubicin	pirarubicin	O	O	OTHERS	I
plasma	plasma	O	O	O	O
T	t	O	O	O	O
1/2	1/2	O	O	O	O
alpha	alpha	O	O	O	O
(	(	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
SE	se	O	DISEASE	OTHERS	I
)	)	O	O	O	O
of	of	O	O	O	O
2.5	2.5	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
0.85	0.85	O	O	O	O
minutes	minutes	O	O	O	O
,	,	O	O	O	O
T	t	O	O	O	O
beta	beta	O	O	O	O
1/2	1/2	O	O	O	O
of	of	O	O	O	O
25.6	25.6	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
6.5	6.5	O	O	O	O
minutes	minutes	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
T	t	O	O	O	O
1/2	1/2	O	O	O	O
gamma	gamma	O	O	O	O
of	of	O	O	O	O
23.6	23.6	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
7.6	7.6	O	O	O	O
hours	hours	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
area	area	O	O	O	O
under	under	O	O	O	O
the	the	O	O	O	O
curve	curve	O	O	O	O
was	was	O	O	O	O
537	537	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
149	149	O	O	O	O
ng/ml	ng/ml	O	O	O	O
x	x	O	O	O	O
hours	hours	O	O	O	O
,	,	O	O	O	O
volume	volume	O	O	O	O
of	of	O	O	O	O
distribution	distribution	O	O	O	O
(	(	O	O	O	O
Vd	vd	O	O	O	O
)	)	O	O	O	O
3504	3504	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
644	644	O	O	O	O
l/m2	l/m2	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
total	total	O	O	O	O
clearance	clearance	O	O	O	O
(	(	O	O	O	O
ClT	clt	O	O	O	O
)	)	O	O	O	O
was	was	O	O	O	O
204	204	O	O	O	O
+	+	O	O	O	O
39.3	39.3	O	O	O	O
l/hour/m2	l/hour/m2	O	O	O	O
.	.	O	O	O	O

Adriamycinol	adriamycinol	O	O	OTHERS	I
,	,	O	O	O	O
doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
adriamycinone	adriamycinone	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
tetrahydropyranyladriamycinol	tetrahydropyranyladriamycinol	O	O	OTHERS	I
were	were	O	O	O	O
the	the	O	O	O	O
metabolites	metabolites	O	O	O	O
detected	detected	O	O	O	O
in	in	O	O	O	O
plasma	plasma	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
amount	amount	O	O	O	O
of	of	O	O	O	O
doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
less	less	O	O	O	O
than	than	O	O	O	O
or	or	O	O	O	O
equal	equal	O	O	O	O
to	to	O	O	O	O
10	10	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
total	total	O	O	O	O
metabolites	metabolites	O	O	O	O
.	.	O	O	O	O

Urinary	urinary	O	O	O	O
excretion	excretion	O	O	O	O
of	of	O	O	O	O
Pirarubicin	pirarubicin	O	O	OTHERS	I
in	in	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
24	24	O	O	O	O
hours	hours	O	O	O	O
was	was	O	O	O	O
less	less	O	O	O	O
than	than	O	O	O	O
or	or	O	O	O	O
equal	equal	O	O	O	O
to	to	O	O	O	O
10	10	O	O	O	O
%	%	O	O	O	O
.	.	O	O	O	O

Activity	activity	O	O	O	O
was	was	O	O	O	O
noted	noted	O	O	O	O
in	in	O	O	O	O
mesothelioma	mesothelioma	O	O	OTHERS	I
,	,	O	O	O	O
leiomyosarcoma	leiomyosarcoma	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
basal	basal	O	O	OTHERS	I
cell	cell	O	O	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
recommended	recommended	O	O	O	O
starting	starting	O	O	O	O
dose	dose	O	O	O	O
for	for	O	O	O	O
Phase	phase	O	O	O	O
II	ii	O	O	O	O
trials	trials	O	O	O	O
is	is	O	O	O	O
60	60	O	O	O	O
mg/m2	mg/m2	O	O	O	O
IV	iv	O	O	O	O
bolus	bolus	O	O	O	O
every	every	O	O	O	O
3	3	O	O	O	O
weeks	weeks	O	O	O	O
.	.	O	O	O	O

